Disc Med­i­cine pays $10M up­front for mon­o­clon­al an­ti­body for rare blood dis­or­der, can­cer

Hema­tol­ogy-fo­cused Disc Med­i­cine has agreed to pay a $10 mil­lion down pay­ment to Mab­well Ther­a­peu­tics to de­vel­op and com­mer­cial­ize a port­fo­lio of mon­o­clon­al an­ti­bod­ies for blood dis­or­ders.

It’s the first deal Disc has made since it went pub­lic in Au­gust.

The ini­tial $10 mil­lion is a small piece of a po­ten­tial $412.5 mil­lion of mile­stone pay­ments and roy­al­ties of “close to two dig­it per­cent­age” of net sales. Disc will have rights in the US, Eu­rope and oth­er un­named ter­ri­to­ries out­side of Chi­na and South­east Asia. The mon­o­clon­al an­ti­bod­ies tar­get trans­mem­brane ser­ine pro­tease 6.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER